The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

If your non-small cell lung cancer (NSCLC) involves a gene mutation, you may receive a targeted therapy. These medications address specific gene mutations more effectively than standard cancer ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...